Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sunitinib 2Erlotinib Hydrochloride 2trastuzumab deruxtecan 1tinostamustine 1spartalizumab 1ripretinib 1ribociclib 1pexidartinib 1pembrolizumab 1motexafin lutetium 1Thalidomide 1Psychiatric Rehabilitation 1OSI 930 1Midazolam 1Irinotecan 1Injections 1Fentanyl 1Early Intervention, Educational 1Drug Therapy 1Docetaxel 1Counseling 1Cisplatin 1Cetuximab 1Capecitabine 1Caffeine 17-hydroxystaurosporine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Caffeine × Thoracic × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡